Download Free Medical Management of Patients With Ventricular Arrhythmias and Prevention of Sudden Cardiac Death PowerPoint Presentation

Management of Patients With Ventricular Arrhythmias and Prevention of Sudden Cardiac Death PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Emergency Medical Services (EMS), which is titled "Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death", to know about the AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

Tags : Emergency Medical Services, EMS, Guideline, Management, Patients, Ventricular Arrhythmias, Prevention, Sudden Cardiac Death

Published on : Aug 06, 2021 | Views : 1600 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Developed in Collaboration With the Heart Failure Society of America Endorsed by Heart Failure Society of America © American College of Cardiology Foundation and American Heart Association
Slide 2-

Citation This slide set is adapted from the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Published on [Date], available at: Journal of the American College of Cardiology [(insert full link)] and Circulation [(insert full link)] The full-text guidelines are also available on the following Web sites: ACC (www.acc.org) and AHA (professional.heart.org)
Slide 3-

VA/SCD Guideline Writing Committee Sana M. Al-Khatib, MD, MHS, FACC, FAHA, FHRS, Chair William G. Stevenson, MD, FACC, FAHA, FHRS, Vice Chair †ACC/AHA Representative. ‡HRS Representative. §ACC/AHA Task Force on Performance Measures Liaison/HFSA Representative. ║ACC/AHA Task Force on Clinical Practice Guidelines Liaison. Richard L. Page, MD, FACC, FAHA, FHRS‡
Slide 4-

Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)
Slide 5-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death General Evaluation of Patients with Documented or Suspected VA
Slide 6-

History and Physical Examination *This section covers practices that are well accepted, and a new recommendation was determined to only be warranted for syncope.
Slide 7-

12-lead ECG and Exercise Testing Noninvasive Evaluation
Slide 8-

Ambulatory Electrocardiography Noninvasive Evaluation Implanted Cardiac Monitors
Slide 9-

Noninvasive Cardiac Imaging Noninvasive Evaluation
Slide 10-

Biomarkers Noninvasive Evaluation Genetic Considerations in Arrhythmia Syndromes
Slide 11-

Invasive Cardiac Imaging: Cardiac Catheterization or CT Angiography Invasive Evaluation
Slide 12-

Electrophysiological Study for VA Invasive Evaluation
Slide 13-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Therapies for Treatment or Prevention of VA
Slide 14-

Preventing SCD with HF Medications
Slide 15-

Surgery and Revascularization Procedures in Patients With Ischemic Heart Disease
Slide 16-

Surgery for Arrhythmia Management Surgery and Revascularization Procedures in Patients With IHD
Slide 17-

Autonomic Modulation
Slide 18-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Acute Management of Specific VA
Slide 19-

Acute Management of Specific VA
Slide 20-

Acute Management of Specific VA (contd.)
Slide 21-

Acute Management of Specific VA (contd.)
Slide 22-

Colors correspond to Class of Recommendation in Table 1. *Known history of Verapamil sensitive or classical ECG presentation. ACLS indicates advanced cardiovascular life support; ECG, electrocardiogram; VA, ventricular arrhythmia; and VT, ventricular tachycardia. Management of Sustained Monomorphic VT
Slide 23-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Ongoing Management of VA and SCD Risk Related to Specific Disease States
Slide 24-

Secondary Prevention of SCD in Patients With Ischemic Heart Disease Ischemic Heart Disease
Slide 25-

Colors correspond to Class of Recommendation in Table 1. *Exclude reversible causes. †History consistent with an arrhythmic etiology for syncope. ║ICD candidacy as determined by functional status, life expectancy, or patient preference. EP indicates electrophysiological; GDMT, guideline-directed management and therapy; ICD, implantable cardioverter-defibrillator; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; SCA, sudden cardiac arrest; SCD, sudden cardiac death; and VT, ventricular tachycardia Secondary Prevention Patients With IHD
Slide 26-

Secondary Prevention of SCD in Patients With Ischemic Heart Disease Coronary Artery Spasm Ischemic Heart Disease
Slide 27-

Primary Prevention of SCD in Patients With Ischemic Heart Disease Ischemic Heart Disease
Slide 28-

Primary Prevention of SCD in Patients With Ischemic Heart Disease (contd.) Ischemic Heart Disease
Slide 29-

Primary Prevention of SCD in Patients With Ischemic Heart Disease (contd.) Ischemic Heart Disease
Slide 30-

Colors correspond to Class of Recommendation in Table 1. *Advanced HF therapy includes CRT, cardiac transplant, and LVAD. †Scenarios exist for early ICD placement in select circumstances such as patients with a pacing indication or syncope thought due to VT. These are detailed elsewhere in a HRS/ACC/AHA expert consensus statement. CRT indicates cardiac resynchronization therapy; EP, electrophysiological; GDMT, guideline-directed management and therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; VT, ventricular tachycardia; and WCD, wearable cardioverter-defibrillator. Primary Prevention of SCD in Patients With Ischemic Heart Disease
Slide 31-

Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease Ischemic Heart Disease
Slide 32-

Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease (contd.) Ischemic Heart Disease
Slide 33-

Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease (contd.) Ischemic Heart Disease
Slide 34-

Treatment of Recurrent VA in Patients With Ischemic Heart Disease or NICM Colors correspond to Class of Recommendation in Table 1. *Management should start with ensuring that the ICD is programmed appropriately and that potential precipitating causes, including heart failure exacerbation, are addressed. For information regarding optimal ICD programming, refer to the 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement. APHRS indicates Asia Pacific Heart Rhythm Society; EHRA, European Heart Rhythm Association; HRS, Heart Rhythm Society; IHD, ischemic heart disease; ICD, implantable cardioverter-defibrillator; PVC, premature ventricular complex; NICM, nonischemic cardiomyopathy; SOLAECE, Sociedad Latinoamericana de Estimulación Cardíaca y Electroﬁsiología; VF, ventricular fibrillation; and VT, ventricular tachycardia.
Slide 35-

Nonischemic Cardiomyopathy
Slide 36-

Nonischemic Cardiomyopathy Secondary Prevention of SCD in Patients With NICM
Slide 37-

Nonischemic Cardiomyopathy Primary Prevention of SCD in Patients With NICM
Slide 38-

Nonischemic Cardiomyopathy Primary Prevention of SCD in Patients With NICM (contd.)
Slide 39-

Nonischemic Cardiomyopathy Treatment of Recurrent VA in Patients With NICM
Slide 40-

Colors correspond to Class of Recommendation in Table 1. *ICD candidacy as determined by functional status, life expectancy or patient preference. 2° indicates secondary; EP, electrophysiological; GDMT, guideline-directed management and therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NICM, nonischemic cardiomyopathy; SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA, ventricular arrhythmia; and WCD, wearable cardiac-defibrillator. Secondary and Primary Prevention of SCD in Patients With NICM
Slide 41-

Arrhythmogenic Right Ventricular Cardiomyopathy
Slide 42-

Arrhythmogenic Right Ventricular Cardiomyopathy (contd.)
Slide 43-

Arrhythmogenic Right Ventricular Cardiomyopathy (contd.)
Slide 44-

Hypertrophic Cardiomyopathy
Slide 45-

Hypertrophic Cardiomyopathy (contd.)
Slide 46-

Hypertrophic Cardiomyopathy (contd.)
Slide 47-

Hypertrophic Cardiomyopathy (contd.)
Slide 48-

Myocarditis
Slide 49-

Cardiac Sarcoidosis
Slide 50-

Cardiac Sarcoidosis (contd.)
Slide 51-

Colors correspond to Class of Recommendation in Table 1. *ICD candidacy as determined by functional status, life expectancy, or patient preference. †For recurrent sustained monomorphic VT, refer to Figure Management of Sustained Monomorphic VT. CEP indicates electrophysiological; GDMT, guideline-directed management and therapy; ICD, implantable cardiac-defibrillator; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PET, positron emission tomography; SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA, ventricular arrhythmia; and VT, ventricular tachycardia. Prevention of SCD in Patients With Cardiac Sarcoidosis
Slide 52-

Heart Failure HF With Reduced Ejection Fraction Left Ventricular Assist Device
Slide 53-

Heart Failure ICD Use After Heart Transplantation
Slide 54-

Neuromuscular Disorders
Slide 55-

Cardiac Channelopathies
Slide 56-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Congenital Long QT Syndrome
Slide 57-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Congenital Long QT Syndrome (contd.)
Slide 58-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Congenital Long QT Syndrome (contd.)
Slide 59-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Congenital Long QT Syndrome (contd.)
Slide 60-

Colors correspond to Class of Recommendation in Table 1. *ICD candidacy as determined by functional status, life expectancy, or patient preference. †High-risk patients with LQTS include those with QTc >500 ms, genotypes LQT2 and LQT3, females with genotype LQT2, <40 years of age, onset of symptoms at <10 years of age, and patients with recurrent syncope ICD indicates implantable cardioverter-defibrillator; LQTS, long-QT syndrome; VT, ventricular tachycardia. Prevention of SCD in Patients With Long QT Syndrome
Slide 61-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Catecholaminergic Polymorphic Ventricular Tachycardia
Slide 62-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Brugada Syndrome
Slide 63-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Brugada Syndrome (contd.)
Slide 64-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Brugada Syndrome (contd.) SR indicates systematic review.
Slide 65-

Colors correspond to Class of Recommendation in Table 1. *ICD candidacy as determined by functional status, life expectancy or patient preference. 1° indicates primary; ECG, electrocardiogram; EP, electrophysiological; ICD implantable cardioverter-defibrillator; SCD, sudden cardiac death; VT, ventricular tachycardia; and VF, ventricular fibrillation. Prevention of SCD in Patients With Brugada Syndrome
Slide 66-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Early Repolarization “J-wave” Syndrome
Slide 67-

Cardiac Channelopathies Specific Cardiac Channelopathy Syndromes Short QT Syndrome
Slide 68-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death VA in the Structurally Normal Heart
Slide 69-

VA in the Structurally Normal Heart
Slide 70-

Outflow Tract and AV Annular VA
Slide 71-

Papillary Muscle VA
Slide 72-

Interfascicular Reentrant VT (Belhassen Tachycardia)
Slide 73-

Idiopathic Polymorphic VT/VF
Slide 74-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death PVC-Induced Cardiomyopathy
Slide 75-

PVC-Induced Cardiomyopathy
Slide 76-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death VA and SCD Related to Specific Populations
Slide 77-

Pregnancy
Slide 78-

SR indicates systematic review. Older Patients With Comorbidities
Slide 79-

Medication-Induced Arrhythmias
Slide 80-

Medication-Induced Arrhythmias
Slide 81-

Adult Congenital Heart Disease
Slide 82-

Adult Congenital Heart Disease (contd.)
Slide 83-

Adult Congenital Heart Disease (contd.)
Slide 84-

Adult Congenital Heart Disease (contd.)
Slide 85-

Colors correspond to Class of Recommendation in Table 1. *High-risk features: prior palliative systemic to pulmonary shunts, unexplained syncope, frequent PVC, atrial tachycardia, QRS duration ≥180 ms, decreased LVEF or diastolic dysfunction, dilated right ventricle, severe pulmonary regurgitation or stenosis, or elevated levels of BNP. †Frequent VA refers to frequent PVCs and/or nonsustained VT. ACHD indicates adult congenital heart disease; BNP, B-type natriuretic peptide; EP, electrophysiological; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; PVC, premature ventricular complexes; SCD, sudden cardiac death; TOF, tetralogy of Fallot; VA, ventricular arrhythmia; and VT, ventricular tachycardia. Prevention of SCD in Patients With Adult Congenital Heart Disease
Slide 86-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Defibrillators Other than Transvenous ICDs
Slide 87-

Subcutaneous Implantable Cardioverter-Defibrillator
Slide 88-

Wearable Cardioverter-Defibrillator
Slide 89-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Special Considerations for Catheter Ablation
Slide 90-

Special Considerations for Catheter Ablation
Slide 91-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Post-Mortem Evaluation of SCD
Slide 92-

Post-Mortem Evaluation of SCD
Slide 93-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Terminal Care
Slide 94-

Terminal Care
Slide 95-

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Shared Decision Making
Slide 96-

Shared Decision Making